Paul R. Billings
YOU?
Author Swipe
View article: Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial
Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial Open
Background: Epidemiological studies suggest lung cancer results from the combined effects of smoking and genetic susceptibility. The clinical application of polygenic risk scores (PRSs), derived from combining the results from multiple ger…
View article: Single step capture and assessment of multiple plasma extracellular vesicle biomarkers in Alzheimer’s disease detection
Single step capture and assessment of multiple plasma extracellular vesicle biomarkers in Alzheimer’s disease detection Open
Background Blood tests for Alzheimer’s disease (AD) that measure biomarkers could be useful as minimally‐invasive ways to give patients more and earlier access to screening. While some AD biomarkers can be detected in plasma, they need to …
View article: Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma
Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma Open
Background Pancreatic ductal adenocarcinoma (PDAC) has an overall 5-year survival rate of just 12.5% and thus is among the leading causes of cancer deaths. When detected at early stages, PDAC survival rates improve substantially. Testing h…
View article: Case Report: Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy
Case Report: Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy Open
Background The detection of pancreatic ductal adenocarcinoma (PDAC) lesions at pre-cancerous or early-stages is critical to improving patient survival. We have developed a liquid biopsy test (ExoVita ® ) based on the measurement of protein…
View article: Supplementary Table 4 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 4 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 42K, Ingenuity Canonical Pathways results for mTNBC based on edgeR differential expression results
View article: Supplementary Table 7 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 7 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 61K, List of somatic point mutations in mTNBC detected by NGS sequencing analysis
View article: Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 273K, Somatic genic focal copy number changes in mTNBC
View article: Data from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Data from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
Triple-negative breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2. Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor …
View article: Supplementary Figure 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Figure 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
PDF file - 1635K, PET/CT images of mTNBC2 breast lesion before and after treatment on combination MEK and AKT inhibitors
View article: Supplementary Table 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 598K, edgeR differential expression results in mTNBC for select cancer related genes
View article: Supplementary Table 6 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 6 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 23K, Mapping statistics for genome sequencing of tumor and germline DNA from mTNBC
View article: Supplementary Table 9 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 9 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 45K, Genes containing breakpoint from translocation in mTNBC
View article: Supplementary Figure 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Figure 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
PDF file - 72K, Profiles of germline/tumor single base mutations by genotype in mTNBC
View article: Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 607K, Outlier differential expression results in mTNBC for select cancer related genes
View article: Supplementary Figure 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Figure 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
PDF file - 135K, Validation of RB1 39bp homozygous deletion in mTNBC1
View article: Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 273K, Somatic genic focal copy number changes in mTNBC
View article: Supplementary Table 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 40K, Characteristics of mTNBC study population
View article: Supplementary Table 7 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 7 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 61K, List of somatic point mutations in mTNBC detected by NGS sequencing analysis
View article: Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 607K, Outlier differential expression results in mTNBC for select cancer related genes
View article: Supplementary Table 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 598K, edgeR differential expression results in mTNBC for select cancer related genes
View article: Data from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Data from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
Triple-negative breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2. Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor …
View article: Supplementary Table 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 40K, Characteristics of mTNBC study population
View article: Supplementary Figure 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Figure 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
PDF file - 135K, Validation of RB1 39bp homozygous deletion in mTNBC1
View article: Supplementary Table 9 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 9 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 45K, Genes containing breakpoint from translocation in mTNBC
View article: Supplementary Table 4 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 4 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 42K, Ingenuity Canonical Pathways results for mTNBC based on edgeR differential expression results
View article: Supplementary Table 6 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 6 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 23K, Mapping statistics for genome sequencing of tumor and germline DNA from mTNBC
View article: Supplementary Table 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 48K, Transcriptome sequencing (RNA-seq) run statistics for mTNBC
View article: Supplementary Figure 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Figure 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
PDF file - 1635K, PET/CT images of mTNBC2 breast lesion before and after treatment on combination MEK and AKT inhibitors
View article: Supplementary Figure 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Figure 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
PDF file - 72K, Profiles of germline/tumor single base mutations by genotype in mTNBC
View article: Supplementary Table 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 48K, Transcriptome sequencing (RNA-seq) run statistics for mTNBC